MCID: OVR059
MIFTS: 48

Ovary Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases, Rare diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Ovary Adenocarcinoma

MalaCards integrated aliases for Ovary Adenocarcinoma:

Name: Ovary Adenocarcinoma 11 14
Ovarian Adenocarcinoma 11 58 28 5 16 71
Adenocarcinoma of the Ovary 11
Adenocarcinoma of Ovary 58
Ovarian Adenoacanthoma 11

Characteristics:


Prevelance:

Adenocarcinoma of Ovary: 1-9/100000 58

Age Of Onset:

Adenocarcinoma of Ovary: Adult 58

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 11 DOID:3713
NCIt 49 C7700
ICD10 via Orphanet 32 C56
UMLS via Orphanet 72 C0948216
Orphanet 58 ORPHA213504
UMLS 71 C0948216

Summaries for Ovary Adenocarcinoma

Disease Ontology: 11 An ovarian carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary: Ovary Adenocarcinoma, also known as ovarian adenocarcinoma, is related to endometrioid ovary carcinoma and clear cell adenocarcinoma. An important gene associated with Ovary Adenocarcinoma is INHBA (Inhibin Subunit Beta A), and among its related pathways/superpathways are Endometrial cancer and Immune response IL-23 signaling pathway. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include ovary, endothelial and lymph node, and related phenotypes are Increased shRNA abundance (Z-score > 2) and neoplasm

Related Diseases for Ovary Adenocarcinoma

Diseases related to Ovary Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 516)
# Related Disease Score Top Affiliating Genes
1 endometrioid ovary carcinoma 32.2 TP53 KRAS HRAS H2AC18 ARID1A
2 clear cell adenocarcinoma 31.8 TP53 INHBA ARID1A
3 appendix adenocarcinoma 31.6 TP53 KRAS HRAS CEACAM5
4 mucinous adenocarcinoma 31.5 TP53 KRAS HRAS ERBB2 CEACAM5
5 ovarian cystadenocarcinoma 31.5 TP53 SERPINA3 MIR744 MIR30A MIR196A1 MIR17
6 serous cystadenocarcinoma 31.3 TP53 MIR30A MIR152 KRAS HRAS H2AC18
7 ovarian clear cell adenocarcinoma 31.2 TP53 H2AC18 ESS2 ARID1A
8 ovarian cancer 31.1 TP53 MIR30A MIR29C MIR196A1 MIR17 KRAS
9 papillary adenocarcinoma 31.1 TP53 MIR30A KRAS HRAS ERBB2 CEACAM5
10 adenoid squamous cell carcinoma 31.1 TP53 CEACAM5
11 adenofibroma 31.0 TP53 KRAS ARID1A
12 cystadenocarcinoma 31.0 TP53 SERPINA3 MIR30A KRAS CEACAM5 BRCA1
13 papillary serous adenocarcinoma 30.9 TP53 MIR30A KRAS HRAS ESS2 ERBB2
14 pseudomyxoma peritonei 30.8 TP53 KRAS CEACAM5
15 fallopian tube carcinoma 30.8 TP53 ERBB2 BRCA1
16 endometrial cancer 30.7 TP53 MIR30A MIR152 KRAS HRAS H2AC18
17 adenocarcinoma 30.6 TP53 KRAS HRAS ERBB2 CEACAM5 BAX
18 cystadenoma 30.6 SERPINA3 CEACAM5 BRCA1
19 carcinosarcoma 30.6 TP53 KRAS HRAS ERBB2
20 endometrial adenocarcinoma 30.6 TP53 SERPINA3 MIR152 KRAS
21 mucinous cystadenocarcinoma 30.5 SERPINA3 KRAS HRAS CEACAM5
22 ovarian serous carcinoma 30.5 TP53 HRAS H2AC18 BRCA1
23 teratoma 30.5 TP53 KRAS ERBB2 CEACAM5
24 pilocytic astrocytoma 30.5 TP53 SERPINA3 KRAS HRAS
25 rectal benign neoplasm 30.5 TP53 MIR17 KRAS HRAS CEACAM5
26 myoma 30.5 TP53 KRAS CEACAM5
27 small-cell carcinoma of the ovary of hypercalcemic type 30.5 TP53 ARID1A
28 endometrial hyperplasia 30.4 TP53 KRAS ARID1A
29 meningioma, familial 30.4 TP53 SERPINA3 HRAS H2AC18 ERBB2
30 female reproductive endometrioid cancer 30.4 TP53 KRAS HRAS ERBB2 BRCA1 ARID1A
31 colonic benign neoplasm 30.4 TP53 SERPINA3 KRAS HRAS H2AC18 ERBB2
32 colorectal adenocarcinoma 30.4 TP53 MIR17 KRAS HRAS H2AC18 ERBB2
33 rectum cancer 30.4 TP53 MIR30A MIR17 KRAS HRAS H2AC18
34 lymphatic system disease 30.4 TP53 SERPINA3 MIR30A MIR29C MIR196A1 MIR17
35 colon adenocarcinoma 30.4 TP53 KRAS HRAS CEACAM5 BAX ARID1A
36 ovarian clear cell carcinoma 30.3 TP53 KRAS HRAS H2AC18 ESS2 BRCA1
37 vaginal cancer 30.3 TP53 HRAS BRCA1
38 ovarian mucinous cystadenocarcinoma 30.3 SERPINA3 CEACAM5
39 adenocarcinoma in situ 30.3 TP53 KRAS HRAS CEACAM5
40 bladder cancer 30.3 TP53 MIR29C MIR17 KRAS HRAS H2AC18
41 squamous cell carcinoma 30.2 TP53 KRAS HRAS ERBB2 CEACAM5
42 skin melanoma 30.2 TP53 KRAS HRAS H2AC18 ERBB2
43 cervical squamous cell carcinoma 30.2 TP53 KRAS CEACAM5 ARID1A
44 endocervical adenocarcinoma 30.2 TP53 HRAS ERBB2 CEACAM5 ARID1A
45 gallbladder disease 30.2 TP53 SERPINA3 MIR30A MIR29C MIR196A1 MIR17
46 ovarian disease 30.2 TP53 MIR30A MIR17 H2AC18 ERBB2 BRCA1
47 gastrointestinal stromal tumor 30.1 TP53 SERPINA3 KRAS HRAS H2AC18 ERBB2
48 ovarian carcinosarcoma 30.1 TP53 KRAS HRAS H2AC18 ERBB2 BRCA1
49 thyroid gland cancer 30.1 TP53 MIR17 KRAS HRAS H2AC18 ERBB2
50 rhabdomyosarcoma 30.0 TP53 MIR29C KRAS HRAS ERBB2 CEACAM5

Graphical network of the top 20 diseases related to Ovary Adenocarcinoma:



Diseases related to Ovary Adenocarcinoma

Symptoms & Phenotypes for Ovary Adenocarcinoma

GenomeRNAi Phenotypes related to Ovary Adenocarcinoma according to GeneCards Suite gene sharing:

25 (show all 22)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.72 KRAS
2 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.72 BRCA1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-139 9.72 BRCA1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.72 ERBB2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.72 ARID1A BRCA1 ERBB2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.72 ARID1A
7 Increased shRNA abundance (Z-score > 2) GR00366-A-186 9.72 ARID1A
8 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.72 ARID1A
9 Increased shRNA abundance (Z-score > 2) GR00366-A-204 9.72 BRCA1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.72 ERBB2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-211 9.72 BRCA1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.72 ARID1A
13 Increased shRNA abundance (Z-score > 2) GR00366-A-22 9.72 KRAS
14 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.72 ERBB2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.72 ARID1A
16 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.72 ERBB2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.72 ERBB2 KRAS
18 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.72 ARID1A
19 Increased shRNA abundance (Z-score > 2) GR00366-A-82 9.72 H2AC18
20 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.72 ERBB2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-87 9.72 ERBB2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.72 H2AC18

MGI Mouse Phenotypes related to Ovary Adenocarcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.76 ARID1A BAX BRCA1 CEACAM5 ERBB2 HRAS
2 muscle MP:0005369 9.61 ARID1A BAX BRCA1 CEACAM5 ERBB2 HRAS
3 skeleton MP:0005390 9.32 ARID1A BAX BRCA1 C1RL ERBB2 HRAS

Drugs & Therapeutics for Ovary Adenocarcinoma

Drugs for Ovary Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 60)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
2
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
3
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
4
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
5 Albumin-Bound Paclitaxel Phase 3
6 Antimitotic Agents Phase 3
7 Tubulin Modulators Phase 3
8 Estrogens Phase 3
9 Estrogen Receptor Antagonists Phase 3
10 Estrogen Antagonists Phase 3
11 Hormones Phase 3
12 Hormone Antagonists Phase 3
13 Aromatase Inhibitors Phase 3
14
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
15
Nintedanib Approved Phase 2 656247-17-5 135423438 9809715
16
Levoleucovorin Approved, Experimental, Investigational Phase 1, Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
17
Nivolumab Approved Phase 2 946414-94-4
18
Ipilimumab Approved Phase 2 477202-00-9
19
Fludarabine Approved Phase 1, Phase 2 75607-67-9, 21679-14-1 30751 657237
20
Niraparib Approved, Investigational Phase 2 1038915-60-4 24958200
21
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
22
Aldesleukin Approved Phase 2 110942-02-4
23
Sargramostim Approved, Investigational Phase 2 123774-72-1
24
Folic acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
25
Spartalizumab Investigational Phase 2 1935694-88-4
26
Exatecan Investigational Phase 1, Phase 2 171335-80-1 18546929 151115
27
Oregovomab Investigational Phase 2 213327-37-8
28
Molgramostim Investigational Phase 2 99283-10-0
29 Angiogenesis Inhibitors Phase 2
30 Immunoglobulins, Intravenous Phase 2
31 Immunoglobulin G Phase 2
32 Endothelial Growth Factors Phase 2
33 Mitogens Phase 2
34 Protein Kinase Inhibitors Phase 2
35 Immune Checkpoint Inhibitors Phase 2
36 Folate Phase 1, Phase 2
37 Vitamin B9 Phase 1, Phase 2
38 Vitamin B Complex Phase 1, Phase 2
39 Interleukin-2 Phase 1, Phase 2
40 Poly(ADP-ribose) Polymerase Inhibitors Phase 2
41 Immunoglobulins Phase 2
42 Antibodies Phase 2
43 Antineoplastic Agents, Immunological Phase 2
44 Antibodies, Monoclonal Phase 2
45 Immunologic Factors Phase 2
46 Vaccines Phase 2
47 Antiviral Agents Phase 2
48 Anti-Infective Agents Phase 2
49 Anti-Retroviral Agents Phase 2
50 Adjuvants, Immunologic Phase 2

Interventional clinical trials:

(show all 19)
# Name Status NCT ID Phase Drugs
1 Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer: a Randomized Phase III Trial (LEPRE Trial) Recruiting NCT05601700 Phase 3 Letrozole tablets;carboplatin AUC 5 and paclitaxel 175 mg/m2
2 OVax®: A Feasibility Study Using a DNP-Modified Autologous Ovarian Tumor Cell Vaccine as Therapy in Ovarian Cancer Patients After Relapse: Unknown status NCT00660101 Phase 1, Phase 2
3 Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies. Completed NCT03365791 Phase 2
4 A Randomized Phase II Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT02923739 Phase 2 Paclitaxel
5 Randomized Double Blind Placebo-controlled Phase II Trial of Vargatef® (Nintedanib) in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Adenocarcinoma of the Ovary, the Fallopian Tube or Serous Adenocarcinoma of the Peritoneum Completed NCT01583322 Phase 2 vargatef;placebo
6 Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors Recruiting NCT05001282 Phase 1, Phase 2 ELU001
7 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
8 A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer Recruiting NCT05451849 Phase 1, Phase 2 Fludarabine;Cyclophosphamide
9 A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Expansion Study of AVB-001, an Intraperitoneally Administered, Cell-Generated, Human IL-2 Immunotherapy in Patients With Platinum-Resistant, High-Grade, Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube Recruiting NCT05538624 Phase 1, Phase 2 AVB-001 (Dose Escalation Phase);AVB-001 (Dose Expansion Phase)
10 Phase 2, Single Arm Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Niraparib as a Combinatorial Immune Priming Strategy in Subjects With Platinum Sensitive Recurrent Ovarian Cancer Recruiting NCT05335993 Phase 2 Niraparib
11 Randomized Phase II Trial Evaluating Compliance With Monitoring Conducted Either by a Hospital-based Physician in Person or by a Nurse in Remote Monitoring Not yet recruiting NCT05500391 Phase 2
12 Phase 2 Randomized Open-label Multicenter Study of Combination of ONC-392 and Pembrolizumab for the Treatment of Patients With Platinum Resistant Ovarian Cancer (PROC) Not yet recruiting NCT05446298 Phase 2 ONC-392;Pembrolizumab
13 Vaccine Therapy With Tumor Specific p53 Peptides in Adult Patients With Low Burden Adenocarcinoma of the Ovary Terminated NCT00001827 Phase 2
14 Phase I Study of Cisplatin Hyperthermic Intraperitoneal Chemotherapy Dose Escalation After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma Previously Treated by Chemotherapy and Completed by Bevacizumab for 15 Months Completed NCT02217956 Phase 1 Cisplatin;Bevacizumab
15 A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FRα Antibody-drug Conjugate) in Adult Patients With Recurrent Endometrial Cancer and Recurrent, High-Grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Recruiting NCT05527184 Phase 1 IMGN151
16 A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women With Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects With Peritoneal Mesothelioma With Recurrence After Prior Chemotherapy Terminated NCT03608618 Phase 1 Cyclophosphamide
17 The CINSARC Genomic Signature as a Predictor of Resectability of High Grade Serous Ovarian Adenocarcinomas Unknown status NCT04248231
18 A Prospective, Longitudinal Study of YKL-40 in Patients With FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Undergoing Primary Chemotherapy Terminated NCT00899093
19 The Effects of Moderate Exercise on Distress, Quality of Life, and Biomarkers of Angiogenesis and Chronic Stress in Ovarian Cancer Survivors - A Randomized Controlled Trial Terminated NCT03641287

Search NIH Clinical Center for Ovary Adenocarcinoma

Genetic Tests for Ovary Adenocarcinoma

Genetic tests related to Ovary Adenocarcinoma:

# Genetic test Affiliating Genes
1 Ovarian Adenocarcinoma 28

Anatomical Context for Ovary Adenocarcinoma

Organs/tissues related to Ovary Adenocarcinoma:

MalaCards : Ovary, Endothelial, Lymph Node, Breast, Bone Marrow, Cervix, T Cells

Publications for Ovary Adenocarcinoma

Articles related to Ovary Adenocarcinoma:

(show top 50) (show all 1491)
# Title Authors PMID Year
1
Prediction of cancer driver mutations in protein kinases. 5
18339846 2008
2
Mixed neuroendocrine/Non-neuroendocrine neoplasm (MiNEN) of gastrointestinal lineage arising in an ovarian mature cystic teratoma. 62
36388757 2022
3
Analysis of bioactive compounds using LC-ESI-MS/MS, cytotoxic, antimicrobial effects, and enzyme activities from Cyclotrichium origanifolium. 62
36366959 2022
4
Green Biosynthesis of Silver Nanoparticles Using Annona glabra and Annona squamosa Extracts with Antimicrobial, Anticancer, Apoptosis Potentials, Assisted by In Silico Modeling, and Metabolic Profiling. 62
36355526 2022
5
Molecular analysis for refractory rare cancers: Sequencing battle continues - learnings for the MOSCATO-01 study. 62
36460264 2022
6
Involvement of Bid in the crosstalk between ferroptotic agent-induced ER stress and TRAIL-induced apoptosis. 62
35994698 2022
7
Suppression of the Antioxidant System and PI3K/Akt/mTOR Signaling Pathway in Cisplatin-Resistant Cancer Cells by Quercetin. 62
36322312 2022
8
Ferrocifen stealth LNCs and conventional chemotherapy: A promising combination against multidrug-resistant ovarian adenocarcinoma. 62
36089209 2022
9
Surgical management of a solitary metastatic ovarian adenocarcinoma with colonic origin presenting as gigantic bilateral ovarian masses. 62
36110333 2022
10
Neuroendocrine Tumor of the Fallopian Tube and Serous Adenocarcinoma of the Ovary: Multicentric Primary Tumors. 62
36178284 2022
11
In Vivo Effects of Conditioned Medium from Human Uterine Cervical Stem Cells in an Ovarian Cancer Xenograft Mouse Model. 62
35985689 2022
12
Anti-Tumoral Effect of Chemerin on Ovarian Cancer Cell Lines Mediated by Activation of Interferon Alpha Response. 62
36077645 2022
13
Ovarian Adenocarcinoma With Leptomeningeal Metastases. 62
36059325 2022
14
Suppression of PI3K/Akt/mTOR Signaling Pathway and Antioxidant System and Reversal of Cancer Cells Resistance to Cisplatin under the Effect of Curcumin. 62
35854021 2022
15
Mesenteric Panniculitis Appears as Metastatic Disease on 18F-FDG-PET/CT Scan. 62
35771041 2022
16
The photodynamic reaction with IR-775 cyanine combined with 2-methoxyestradiol in ovarian (SKOV-3) and human breast adenocarcinoma (MDA MB-231) cell lines. 62
35182779 2022
17
ALCAM/CD166 Is Involved in the Binding and Uptake of Cancer-Derived Extracellular Vesicles. 62
35628559 2022
18
Retroviral association with ovarian adenocarcinoma in laying hens. 62
34807789 2022
19
Ovarian adenocarcinoma in 14-year-old girl. 62
35419802 2022
20
Primary ovarian adenocarcinoma presenting with rubeotic glaucoma and vitritis: A case report. 62
35425610 2022
21
Rare association of the ovarian adenocarcinoma with pregnancy: A case report. 62
35198187 2022
22
Amphiphilic Cell-Penetrating Peptides Containing Natural and Unnatural Amino Acids as Drug Delivery Agents. 62
35406720 2022
23
New flavone, and cytotoxicity activity of Rauia resinosa ethanolic extract and constituents. 62
35142584 2022
24
Patient-Derived Ovarian Cancer Spheroids Rely on PI3K-AKT Signaling Addiction for Cancer Stemness and Chemoresistance. 62
35205706 2022
25
Identification of best housekeeping genes for the normalization of RT-qPCR in human cell lines. 62
34861601 2022
26
StarD13 negatively regulates invadopodia formation and invasion in high-grade serous (HGS) ovarian adenocarcinoma cells by inhibiting Cdc42. 62
34958986 2022
27
Gene co-expression network analysis revealed novel biomarkers for ovarian cancer. 62
36338962 2022
28
A monoclonal antibody against annexin A2 targets stem and progenitor cell fractions in tumors. 62
34715620 2022
29
[(WR)8WKβA]-Doxorubicin Conjugate: A Delivery System to Overcome Multi-Drug Resistance against Doxorubicin. 62
35053417 2022
30
Mesonephric-like Adenocarcinoma of the Ovary: Clinicopathological and Molecular Characteristics. 62
35204416 2022
31
Phytochemical, Cytotoxic, and Antimicrobial Evaluation of Tribulus terrestris L., Typha domingensis Pers., and Ricinus communis L.: Scientific Evidences for Folkloric Uses. 62
35126602 2022
32
Reactive Hemophagocytic Lymphohistiocytosis Secondary to Ovarian Adenocarcinoma: A Rare Case Report. 62
36097636 2022
33
Incidental Finding of Endometrioid Adenocarcinoma of the Ovary on 131I Whole-Body Scan. 62
34028418 2022
34
A 47-year-old man with rare serous cyst adenocarcinoma of the testis. 62
35381807 2022
35
Fatal pulmonary tumour thrombotic microangiopathy in patient with ovarian adenocarcinoma: review and a case report. 62
34986798 2022
36
Intracellular dynamics of the Sigma-1 receptor observed with super-resolution imaging microscopy. 62
35584184 2022
37
Mesonephric-like adenocarcinoma of the ovary in an elderly woman: A case report and a review of the literature. 62
34580958 2021
38
Design and application of hybrid cyclic-linear peptide-doxorubicin conjugates as a strategy to overcome doxorubicin resistance and toxicity. 62
34537446 2021
39
Association of body composition with toxicity to first-line chemotherapy and three-year survival in women with ovarian adenocarcinoma. 62
34634224 2021
40
Cure of Mice with Advanced Ovarian Adenocarcinoma CaO1 by the Serum Blood Proteins. 62
34855090 2021
41
Loss of hexokinase 1 sensitizes ovarian cancer to high-dose metformin. 62
34895333 2021
42
miR-152-mediated MKK7 downregulation is attenuated by MYCNOS in ovarian adenocarcinoma. 62
34733360 2021
43
Spatial transcriptomics at subspot resolution with BayesSpace. 62
34083791 2021
44
Platinum resistance in gynecologic malignancies: Response, disease free and overall survival are predicted by biochemical signature: A metabolomic analysis. 62
34446269 2021
45
Development and identification of a prognostic nomogram model for patients with mixed cell adenocarcinoma of the ovary. 62
34674727 2021
46
Induction of apoptosis on ovarian adenocarcinoma cells, A2780 by tricyclohexylphosphanegold (I) mercaptobenzoate derivatives via intrinsic and extrinsic pathways. 62
34476610 2021
47
Hybrid Cyclic-Linear Cell-Penetrating Peptides Containing Alternative Positively Charged and Hydrophobic Residues as Molecular Transporters. 62
34491768 2021
48
Long-term experience with percutaneous biopsies of pelvic lesions using CT guidance. 62
34918561 2021
49
A case of Endometrioid endometrial adenocarcinoma with synchronous low-grade Appendiceal mucinous neoplasm and Pseudomyxoma peritonei. 62
33605928 2021
50
Preclinical evaluation of anti-VEGFR2 monoclonal antibody ramucirumab labelled with zirconium-89 for tumour imaging. 62
33818828 2021

Variations for Ovary Adenocarcinoma

ClinVar genetic disease variations for Ovary Adenocarcinoma:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 ERBB2 NM_004448.4(ERBB2):c.2570A>G (p.Asn857Ser) SNV Likely Pathogenic
13880 rs28933370 GRCh37: 17:37881378-37881378
GRCh38: 17:39725125-39725125

Copy number variations for Ovary Adenocarcinoma from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 118124 17 7571720 7590868 Mutation TP53 Ovarian adenocarcinomas

Expression for Ovary Adenocarcinoma

Search GEO for disease gene expression data for Ovary Adenocarcinoma.

Pathways for Ovary Adenocarcinoma

Pathways related to Ovary Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.55 TP53 KRAS HRAS ERBB2 BAX
2
Show member pathways
12.41 TP53 KRAS HRAS ERBB2 BAX
3
Show member pathways
12.35 ERBB2 HRAS KRAS TP53
4
Show member pathways
12.34 TP53 HRAS ERBB2 BAX
5
Show member pathways
12.18 TP53 KRAS HRAS ERBB2 BAX
6
Show member pathways
12.17 TP53 KRAS HRAS ERBB2 BRCA1 BAX
7
Show member pathways
12.02 TP53 KRAS HRAS BAX
8
Show member pathways
12.02 TP53 KRAS HRAS ERBB2 BAX
9 11.97 BAX BRCA1 KRAS TP53
10
Show member pathways
11.79 TP53 BRCA1 BAX
11
Show member pathways
11.67 KRAS HRAS BAX
12
Show member pathways
11.67 TP53 KRAS HRAS
13 11.66 TP53 KRAS BAX
14 11.63 TP53 INHBA BAX
15 11.56 TP53 MIR29C MIR17
16 11.49 ERBB2 HRAS KRAS TP53
17 11.48 KRAS HRAS ERBB2
18 11.44 TP53 MIR744 BRCA1
19 11.36 TP53 KRAS HRAS ERBB2 BAX
20 11.21 TP53 BRCA1 BAX
21 11.06 TP53 KRAS HRAS ERBB2
22 11.03 KRAS HRAS ERBB2
23 10.81 TP53 HRAS ERBB2 BRCA1 ARID1A
24
Show member pathways
10.7 KRAS HRAS
25 10.61 TP53 BAX

GO Terms for Ovary Adenocarcinoma

Cellular components related to Ovary Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RISC complex GO:0016442 9.8 MIR744 MIR30A MIR29C MIR196A1 MIR17 MIR152
2 extracellular vesicle GO:1903561 9.02 MIR30A MIR29C MIR17 MIR152 MIR101-1

Biological processes related to Ovary Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 miRNA-mediated gene silencing GO:0035195 10 MIR101-1 MIR152 MIR17 MIR196A1 MIR29C MIR30A
2 negative regulation of gene expression GO:0010629 9.91 TP53 MIR29C MIR17 MIR101-1 HRAS
3 intrinsic apoptotic signaling pathway GO:0097193 9.73 TP53 HRAS BAX
4 regulation of mitochondrial membrane permeability involved in apoptotic process GO:1902108 9.54 TP53 BAX
5 neuron apoptotic process GO:0051402 9.5 TP53 KRAS HRAS BAX
6 positive regulation of mitochondrial membrane permeability involved in apoptotic process GO:1902110 9.4 MIR29C BAX
7 positive regulation of gene expression GO:0010628 9.4 TP53 MIR17 MIR101-1 KRAS INHBA HRAS
8 negative regulation of metalloendopeptidase activity GO:1904684 9.32 MIR29C MIR152

Molecular functions related to Ovary Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.5 TP53 MIR30A MIR29C MIR17 MIR152 MIR101-1
2 mRNA base-pairing translational repressor activity GO:1903231 9.1 MIR30A MIR29C MIR196A1 MIR17 MIR152 MIR101-1

Sources for Ovary Adenocarcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....